Monoclonal gammopathy of undetermined significance (MGUS) in patients with solid tumors: Effects of chemotherapy on the monoclonal protein

Annals of Hematology

Volumn 83, Issue 10, 2004, Pages 658-660

  Anagnostopoulos, Athanasios ^a   Galani, Eleni ^a   Gika, Dimitra ^a   Sotou, Danai ^a   Evangelopoulou, Aikaterini ^a   Dimopoulos, Meletios Athanasios ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Chemotherapy; MGUS; Solid tumors

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; METHOTREXATE; PACLITAXEL; PLASMA PROTEIN; PLATINUM DERIVATIVE; TOPOTECAN; VINBLASTINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; FEMALE; HUMAN; IN VIVO STUDY; MALE; MEDICAL ASSESSMENT; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; PATIENT REFERRAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN ELECTROPHORESIS; SOLID TUMOR;

AGED; ANTINEOPLASTIC AGENTS; BLOOD PROTEIN ELECTROPHORESIS; FEMALE; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN KAPPA-CHAINS; IMMUNOGLOBULIN LAMBDA-CHAINS; IMMUNOGLOBULIN M; MALE; MIDDLE AGED; NEOPLASMS; PARAPROTEINEMIAS; PARAPROTEINS; PROSPECTIVE STUDIES;

EID: 4844230174     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-004-0896-1     Document Type: Article

References (14)

1. The International Myeloma Working Group (2003) Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 121:749-757
2. Hallen J (1966) Discrete gammaglobulin (M)-components in serum. Clinical study of 150 subjects without myelomatosis. Acta Med Scand 180:1
3. Migliore PJ, Alexanian R (1968) Monoclonal gammopathy in human neoplasia. Cancer 21:1127-1131
4. Talerman A, Haije WG (1973) The frequency of M-components in sera of patients with solid malignant neoplasms. Br J Cancer 27:276-282
5. Kelly R (1985) Benign monoclonal gammopathy: a reassessment of the problem. Immunol Invest 14:183-197
6. Gregersen H, Mellemkjaer L, Ibsen JS, Sorensen HT, Olsen JH, Pedersen JO, Dahlerhup JF (2000) Cancer risk in patients with monoclonal gammopathy of undetermined significance. Am J Hematol 63:1-6
7. Anagnostopoulos A, Evangelopoulou A, Sotou D, Gika D, Mitsibounas D, Dimopoulos MA (2002) Incidence and evolution of monoclonal gammopathy of undetermined significance (MGUS) in Greece. Ann Hematol 81:357-361
8. Chen HP, Caroll JA (1980) Monoclonal gammopathy in carcinoma of the colon. Am J Clin Pathol 73:607-610
9. Dimopoulos MA, Arbuck S, Huber M, Weber D, Luckett R, Delasalle K, Alexanian R (1994) Primary therapy of multiple myeloma with paclitaxel (taxol). Ann Oncol 5:757-759
10. Miller HJ, Leong T, Khandekar JD, Greipp PR, Gertz MA, Kyle RA (1998) Paclitaxel as the initial treatment of multiple mycloma: an Eastern Cooperative Oncology Group Study (E1A93). Am J Clin Oncol 21:553-556
11. Friedenberg WR, Graham D, Greipp P, Blood E, Winston RD (2003) The treatment of multiple myeloma with docetaxel (an ECOG study). Leuk Res 27:751-754
12. Burris HA, Fields SM (1994) Topoisomerase I inhibitors. Hematol Oncol Clin North Am 8:333-355
13. Kraut EH, Ju R, Muller M (1998) The use of topoisomerase I inhibitors in multiple myeloma. Semin Hematol 35 [Suppl 4]:32-38
14. Kraut EH, Crowley JJ, Wade JL, Laufman LR, Alsina M, Taylor SA, Salmon SE (1998) Evaluation of topotecan in resistant and relapsing multiple myeloma: a Southwest Oncology Group study. J Clin Oncol 16:589-592